Kai Shunro, Hara Hiroshi
The Department of Transfusion Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Ther Apher Dial. 2003 Jun;7(3):285-91. doi: 10.1046/j.1526-0968.2003.00053.x.
More than 30 years have passed since the first clinical application of allogeneic bone marrow transplantation to treat hematological diseases. In recent years, the availability of peripheral blood and cord blood as additional sources of stem cells other than bone marrow has expanded the applicability of hematopoietic stem cell transplantation. In addition to differences in stem cell content, immune cells in the grafts from the three sources are different in quality and quantity. As a consequence, transplants from different sources have different kinetics of hematological recovery. Stem cell sources also influence risks for developing graft-versus-host disease. In this paper, we review recently reported results of thus diversified allogeneic hematopoietic, stem cell transplantation.
自首次将异基因骨髓移植临床应用于治疗血液系统疾病以来，已经过去了30多年。近年来，除骨髓外，外周血和脐带血作为干细胞的额外来源，扩大了造血干细胞移植的适用性。除了干细胞含量的差异外，这三种来源的移植物中的免疫细胞在质量和数量上也有所不同。因此，来自不同来源的移植具有不同的血液学恢复动力学。干细胞来源也会影响发生移植物抗宿主病的风险。在本文中，我们综述了最近报道的这种多样化的异基因造血干细胞移植的结果。
